Monkey Pcsk9 Antibody 31H4
Human IgG antibody Laboratories manufactures the monkey pcsk9 antibody 31h4 reagents distributed by Genprice. The Monkey Pcsk9 Antibody 31H4 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact monkey Antibody. Other Monkey products are available in stock. Specificity: Monkey Category: Pcsk9 Group: Antibody 31H4
PCSK9 Antibody |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. The protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. |
PCSK9 Antibody |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. The protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. |
PCSK9 Antibody |
EnoGene |
100ul |
EUR 275 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
EnoGene |
100ul |
EUR 275 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
EnoGene |
100ul |
EUR 255 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |
PCSK9 Antibody |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |
Antibody 31H4 information
PCSK9 Antibody |
E8EM1701-26 |
EnoGene |
100ul |
EUR 275 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
E8EM1701-27 |
EnoGene |
100ul |
EUR 275 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
1-CSB-PA017647GA01HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against PCSK9. Recognizes PCSK9 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
PCSK9 Antibody |
1-CSB-PA017647LA01HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against PCSK9. Recognizes PCSK9 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:500-1:1000, IF:1:50-1:200 |
PCSK9 antibody |
E39-06227 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
PCSK9 Antibody |
E97860 |
EnoGene |
100ul |
EUR 255 |
Description: Available in various conjugation types. |
PCSK9 antibody |
70R-19161 |
Fitzgerald |
50 ul |
EUR 289 |
|
Description: Rabbit polyclonal PCSK9 antibody |
PCSK9 Antibody |
1-CSB-PA07039A0Rb |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against PCSK9. Recognizes PCSK9 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
PCSK9 Antibody |
1-CSB-PA638311 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against PCSK9. Recognizes PCSK9 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000 |
PCSK9 Antibody |
1-CSB-PA108805 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against PCSK9. Recognizes PCSK9 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000 |
PCSK9 Antibody |
F52952-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |
PCSK9 Antibody |
F52952-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |